Growth Investor27 commented on a stock · Oct 15, 2024 22:01

Buyout offer Could be $10+ For Esperion And Could Happen Before 2025

$Esperion Therapeutics (ESPR.US)$ The recent analyst note from Jeff sugest Esperion might sell the entire rights for Bempedoic Acid. Fair valuation on the rights would be above $1.5 billion, based on future milestones $900 million, future royalties & patents, the current formulation patent has exp date Dec 2031. The potential yearly sales in the U.S could reach $4 billion by 2027.

Esperion could also partner in the U.S .

Keep an eye on $Amgen (AMGN.US)$ $Novartis AG (NVS.US)$ $Johnson & Johnson (JNJ.US)$ $Merck & Co (MRK.US)$ To look for offers.

Esperion also has a large tax loss carry forward of $1.6 billion Fed & state, so the buyer would see a nice amount of realized losses added to it's books.

I have a friend that is prescribed NEXLIZET and buys if direct from $Amazon (AMZN.US)$ Pharmacy

I believe Esperion will have a great future, selling the only FDA approved primary prevention statin alternative drugs to lower bad cholesterol is a huge market space. Looking at the PCSK9 injection space for Repatha drug by Amgen is on track for over $1 billion in sales for 2024. Repatha works by pulling cholesterol out of the blood & works fast dropping the average LDLc score by 55%, however it doesn't lower Hscrp levels, High-sensitivity C-reactive protein (hs-CRP) levels are a measure of inflammation in the body and indicate the risk of cardiovascular disease and stroke. The American Heart Association and U.S. Centers for Disease Control and Prevention (CDC) use the following risk groups to interpret hs-CRP levels:

Esperion Bempedoic Acid does (NEXLETOL) & NEXLIZET by 25%. Nexlizet lowers LDLC by 40% and in my opinion I would rather take a pill at night than go to the Doctor for an injection twice a month, I don't want to wait at my doctors office and deal with traffic.

I follow JMP securities $7 PT as most reasonable